 2020 VITAS Healthcare and Roto-Rooter Earnings Summary

VITAS Healthcare and Roto-Rooter, two business segments of Chemed Corporation, have shown incredible resilience and adaptability during the pandemic. Despite the disruptions in traditional hospice referral sources and nursing home occupancy, VITAS has maintained its focus on providing care to its patients, families, and referring healthcare partners. The VITAS segment has experienced growth in hospital-generated admissions and a decline in nursing home admissions, resulting in a decrease in average daily census. Roto-Rooter, on the other hand, is forecasted to achieve revenue growth of approximately 5% to 6% with an estimated adjusted EBITDA margin of 26%. Chemed's 2021 revenue is estimated to decline approximately 4% when compared to the prior year, with a full-year adjusted earnings per diluted share estimated in the range of $17 to $17.50. The full-year 2021 adjusted earnings per diluted share excluding non-cash expense for stock options, tax benefits from stock option exercises, cost related to litigation and other discrete items is estimated to be in the range of $17 to $17.50.